[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100616293":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":18,"centralContacts":23,"locations":32,"responsibleParty":52,"collaborators":54,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":62,"acronym":10,"eligibilityCriteria":63,"healthyVolunteers":60,"sex":64,"minAge":65,"maxAge":10,"enrollmentInfo":66,"targetDuration":10,"studyType":69,"phases":10,"briefSummary":70,"conditions":71,"keywords":74,"overallStatus":35,"whyStopped":10,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"Palo Alto Veterans Institute for Research","OTHER",[8,12,15],{"label":9,"type":10,"description":11,"interventionNames":10},"angiography mapping",null,"Hepatocellular carcinoma (HCC) patients undergoing hepatic angiography mapping prior to TARE (N=10)",{"label":13,"type":10,"description":14,"interventionNames":10},"microwave ablation","percutaneous tumor ablation in patients receiving image-guided tumor ablation using MWA (n=10)",{"label":16,"type":10,"description":17,"interventionNames":10},"cryoablation","cryoablation (N=10) for primary liver (HCC) or primary kidney tumors (RCC)",[19],{"name":20,"affiliation":21,"role":22},"Sirish Kishore, MD","VA Palo Alto Health Care System","PRINCIPAL_INVESTIGATOR",[24,29],{"name":20,"role":25,"phone":26,"phoneExt":27,"email":28},"CONTACT","650-493-5000","61706","sirish.kishore@va.gov",{"name":30,"role":25,"phone":26,"phoneExt":27,"email":31},"Luisa Manfredi, MPH","luisa.manfredi1@va.gov",[33],{"facility":34,"status":35,"city":36,"state":37,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"VA Palo Alto Healthcare System","RECRUITING","Palo Alto","California","94304","United States","US",{"type":42,"coordinates":43},"Point",[44,45],-122.14302,37.44188,{"lat":45,"lon":44},[48,49,51],{"name":30,"role":25,"phone":26,"phoneExt":27,"email":31},{"name":20,"role":25,"phone":26,"phoneExt":50,"email":28},"68739",{"name":20,"role":22,"phone":10,"phoneExt":10,"email":10},{"type":53,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[55],{"name":56,"class":57},"Canon Medical Systems, USA","INDUSTRY","100616293","intra-procedural-spectral-ct-for-image-guided-embolization-and-ablation-in-interventional-oncology-100616293",false,"NCT07303725","Intra-procedural Spectral CT for Image-guided Embolization and Ablation in Interventional Oncology","Inclusion criteria:\n\n1. Age \\> or = 18 years\n2. Tumor in an area without prior surgical or ablative therapy\n3. At least 1 tumor greater than 1.5 cm in greatest diameter\n\nExclusion criteria:\n\n1. Not eligible for indicated procedure.\n2. BMI \\> 35\n3. Prior surgery.","ALL","18 Years",{"count":67,"type":68},30,"ESTIMATED","OBSERVATIONAL","This is a pilot study to evaluate the feasibility, image quality, and procedural utility of a novel spectral CT technique using Canon Medical's 4D CT system during image-guided interventional oncology procedures",[72,73],"Liver Cancer (Primary and Metastatic)","Renal Cancer",[75],"spectral CT","2025-12-18",{"date":78,"type":79},"2025-12-26","ACTUAL",{"date":81,"type":79},"2025-02-01",{"date":83,"type":68},"2026-09-01",{"name":5,"class":6},1]